Background:
Industrial production of biofuels and other products by cellulolytic microorganisms is of interest but hindered by the nascent state of genetic tools. Although a genetic system for Clostridium thermocellum DSM1313 has recently been developed, available methods achieve relatively low efficiency and similar plasmids can transform C. thermocellum at dramatically different efficiencies.
Results:
We report an increase in transformation efficiency of C. thermocellum for a variety of plasmids by using DNA that has been methylated by Escherichia coli Dam but not Dcm methylases. When isolated from a dam+ dcm+ E. coli strain, pAMG206 transforms C. thermocellum 100-fold better than the similar plasmid pAMG205, which contains an additional Dcm methylation site in the pyrF gene. Upon removal of Dcm methylation, transformation with pAMG206 showed a four- to seven-fold increase in efficiency; however, transformation efficiency of pAMG205 increased 500-fold. Removal of the Dcm methylation site from the pAM205 pyrF gene via silent mutation resulted in increased transformation efficiencies equivalent to that of pAMG206. Upon proper methylation, transformation efficiency of plasmids bearing the pMK3 and pB6A origins of replication increased ca. three orders of magnitude.
Conclusion:
E. coli Dcm methylation decreases transformation efficiency in C. thermocellum DSM1313. The use of properly methylated plasmid DNA should facilitate genetic manipulation of this industrially relevant bacterium.Source:
http://www.biotechnologyforbiofuels.com/rss/

Background:
The microbial bioemulsifiers was surface active compounds, are more effective in stabilizing oil-in-water emulsions. The yeasts have been isolated to produce bioemulsifiers from vegetable oils and industrial wastes.
Results:
Trichosporon mycotoxinivorans CLA2 is bioemulsifier-producing yeast strain isolated from effluents of the dairy industry, with ability to emulsify different hydrophobic substrates. Bioemulsifier production (mg/L) and the emulsifying activity (E24) of this strain were optimized by response surface methodology using mineral minimal medium containing refinery waste as the carbon source, which consisted of diatomaceous earth impregnated with esters from filters used in biodiesel purification. The highest bioemulsifier production occurred in mineral minimal medium containing 75 g/L biodiesel residue and 5 g/L ammonium sulfate. The highest emulsifying activity was obtained in medium containing 58 g/L biodiesel refinery residue and 4.6 g/L ammonium sulfate, and under these conditions, the model estimated an emulsifying activity of 85%. Gas chromatography and mass spectrometry analysis suggested a bioemulsifier molecule consisting of monosaccharides, predominantly xylose and mannose, and a long chain aliphatic groups composed of octadecanoic acid and hexadecanoic acid at concentrations of 48.01% and 43.16%, respectively. The carbohydrate composition as determined by GC-MS of their alditol acetate derivatives showed a larger ratio of xylose (49.27%), mannose (39.91%), and glucose (10.81%). 1 H NMR spectra confirmed by COSY suggested high molecular weight, polymeric pattern, presence of monosaccharide's and long chain aliphatic groups in the bioemulsifier molecule.
Conclusions:
The biodiesel residue is an economical substrate, therefore seems to be very promising for the low-cost production of active emulsifiers in the emulsification of aromatics, aliphatic hydrocarbons, and kerosene.Source:
http://www.biotechnologyforbiofuels.com/rss/

NEW YORK, May 8, 2012 /PRNewswire/ -- Venture capital (VC) funding in the Life Sciences sector, which includes the Biotechnology and Medical Device industries, decreased 22% during the first quarter of 2012 from the prior quarter, according to a new PwC US report, "Mixed Momentum," that includes data from the PricewaterhouseCoopers LLP/National Venture Capital Association MoneyTree Report, based on data from Thomson Reuters.

(Logo: http://photos.prnewswire.com/prnh/20100917/NY66894LOGO )

Venture capitalists invested a total of $1.5 billion during the first quarter, the lowest level since the fourth quarter of 2010. Deal volume was also down, dropping 11 percent from Q4 to 171 deals. When compared to a year ago, dollars invested into Life Sciences companies during Q1 of 2012 decreased 8 percent while the number of deals declined 12 percent from the $1.6 billion invested in 195 deals during the first quarter of 2011.

For all sectors, venture capitalists invested $5.8 billion in 758 deals in Q1 2012, a decrease of 19 percent in dollars invested and a 15 percent decline in deals, compared to $6.7 billion going into 861 deals in the first quarter of 2011. The Life Sciences share of total venture capital dollars invested stood flat at 26 percent in Q1, a one percent decrease from Q4 2011.

"Venture capitalists remained cautious during the first quarter after a lackluster fourth quarter in the public markets, as evidenced by the shift from investing in earlier stage companies to a focus on later stage companies in Q1," remarked Tracy T. Lefteroff, global managing partner of the venture capital practice at PwC.

During the first quarter, Biotechnology accounted for 53percent of funding, while medical devices claimed 47percent of dollars invested. In comparison, during the fourth quarter of 2011, Biotechnology captured 73 percent of investment in the sector and Medical Devices accounted for 27 percent of the total.

Biotechnology investing decreased by 43percent in dollars and 14 percent in deals, with $780 million going into 99 deals. Despite the drop, Biotechnology ranked second in terms of overall dollars invested, second only to the Software industry. On a year-over-year basis, biotechnology investments decreased 18 percent with deals down 9 percent, with $949million going into 109 deals during the first quarter of 2011.

Medical device investments rose 33 percent in dollars quarter-over-quarter while the number of deals dropped 6 percent during the same time period. With $687 million going into 72 deals in Q1, the Medical Device industry ranked behind Software, Biotechnology, and Industrial/Energy in dollars invested.

"A more active M&A market may be the reason that the Biotech industry experienced a decline in investing in Q1, as VCs saw more of their portfolio companies experience exits during the first quarter," remarked Lefteroff. "While on the surface, the jump in dollars invested in the Medical Device industry during Q1 may seem surprising given the 22% drop in Life Sciences funding overall, a deeper dive shows that companies in the Later stage of development accounted for more than half of the investments in this industry."

First-Time Financing

Link:
Life Sciences Venture Capital Funding Falls 22% in Q1 2012, According to the MoneyTree Report

JEFFERSON COUNTY, AR -- For the second time in three months, an industry chooses to plant roots in Jefferson County. County leaders welcomed Vivione Tuesday.

"It's going to allow us to take the next step in our life cycle to develop products and platforms that can address a lot of the problems we see out here today," said Kevin Kuykendall, the company's CEO.

The company will sell diagnostic test systems to food producers to detect any bacteria. Most companies make tests that reveal results in days, but Vivione's system makes it known in minutes!

"It allows manufacturers to ship their products sooner, provide a safer product, waste less product, less reprocessing if they have to clean and reprocess," said Melinda Miller, the lab manager.

Company leaders looked at other places to open but say Jefferson County leaders offered a deal too good to walk away from. That deal is a result of the economic development tax voters approved last year.

"There is such a tremendous promise for Vivione's future here, a promise for a safer food for our consumers and promise for additional job growth," Lou Ann Nesbitt, the county's economic development alliance, said.

The company employs six people right now, but by 2016, executives plan to have over 100 employees. If you don't have a background in the sciences, don't worry. The company will be looking for people in other arenas to staff. They'll make those positions known at a later date.

Link:
Biotechnology company opens in Jefferson County

Public release date: 8-May-2012 [ | E-mail | Share ]

Contact: Kimberly Brown brownk@aaps.org 703-248-4772 American Association of Pharmaceutical Scientists

WHO: American Association of Pharmaceutical Scientists (AAPS)

WHAT: The 2012 AAPS National Biotechnology Conference (NBC) will gather scientists from industry, government, and academia for three days of educational offerings specifically geared toward the biotechnology sector of the pharmaceutical sciences. The conference kicks off with a brand new advanced Immunogenicity Training Course and two AAPS Workshops, transitions into the 2012 NBC programming, and concludes with three AAPS sponsored short courses. The 2012 programming consists of a Plenary Session, 19 symposia, 17 roundtables (including BioTalk) and mini-symposia, eight sunrise sessions, Posters, and Hot Topics. Additionally, an Exposition Hall will be hosting over 100 major companies.

WHEN: May 21-23, 2012

WHERE: Sheraton San Diego Hotel and Marina, San Diego, CA

Plenary Speakers: C. Anthony Blau, M.D. of the University of Washington; Timothy R. Cot, M.D., MPH of the National Organization for Rare Disorders (NORD); Anthony Coyle, Ph.D. of the Centers for Therapeutic Innovation (CTI).

###

Editor's Note: ALL PRESS MUST BE REGISTERED AND PROVIDE PRESS CREDENTIALS TO ATTEND THIS MEETING. For media registration prior to the conference, please contact Kimberly Brown at 703-248-472 or BrownK@aaps.org.

About AAPS: The American Association of Pharmaceutical Scientists is a professional, scientific society of approximately 12,000 members employed in academia, industry, government and other research institutes worldwide. Founded in 1986, AAPS provides a dynamic international forum for the exchange of knowledge among scientists to serve the public and enhance their contributions to health. AAPS offers timely scientific programs, on-going education, information resources, opportunities for networking, and professional development. Visit http://www.aaps.org today.

See the rest here:
2012 AAPS National Biotechnology Conference heads to San Diego

SEATTLE, May 7, 2012 (GLOBE NEWSWIRE) -- Plandai Biotechnology, Inc., a producer of highly bioavailable plant extracts, today filed a Form 8-K with the Securities and Exchange Commission announcing that it has executed the final loan documents with the Land and Agriculture Bank of South Africa. The total amount of the loan is 100 million Rand (US $13 million).

Plandai Chairman and Chief Executive Officer, Roger Duffield, commented, "Closing this loan is a significant milestone for Plandai because it provides us with the capital necessary to move immediately into production of our highly bioavailable Green Tea extract without causing any dilution to our shareholders. Since first receiving approval for the loan from the Land Bank in December 2011, we have worked diligently to gather the necessary legal documents and ensure compliance with the loan terms. Gratefully, that patience and effort has finally paid off."

In discussing the use of proceeds from the loan, Mr. Duffield added, "We are working on a very short time table in order to reach our goal of having product market ready by early 2013. We have already contracted with our USA engineering partner, CRS Technologies Inc. Delaware, to commence the manufacture of our first hydrodynamic processing and extraction system, in order that we can begin the first commercial, bioavailable Green Tea catechin extract production by the end of the year. At the same time, we have begun work on our Senteeko tea estate to make sure there is suitable and adequate green tea crop available in the last quarter 2012. True to the purpose of the Land Bank loan, we will be employing many of the local Shamile community members to help in the farming and extraction process."

The Land and Agriculture Bank of South Africa (http://www.landbank.co.za/) is a specialist agricultural bank guided by a government mandate to provide financial services to the commercial farming sector and to agri-business and to facilitate access to finance by new entrants to agriculture from historically disadvantaged backgrounds.

About Plandai Biotechnology, Inc.

Plandai Biotechnology, Inc. focuses on the farming of whole fruits, vegetables and live plant material and the production of proprietary functional foods and botanical extracts for the health and wellness industry. Its principle holdings consist of land, farms and infrastructure in South Africa. Web site: http://www.plandaibiotech.com/

Safe Harbor Statement

The information provided may contain forward-looking statements and involve risks and uncertainties. Results, events and performances could vary from those contemplated. These statements involve risks and uncertainties which may cause actual results, expressed or implied, to differ from predicted outcomes. Risks and uncertainties include product demand, market competition, and Plandai's ability to meet current or future plans. Investors should study and understand all risks before making an investment decision. Readers are recommended not to place undue reliance on forward-looking statements or information. Plandai is not obliged to publicly release revisions to any forward-looking statement, to reflect events or circumstances afterward, or to disclose unanticipated occurrences, except as required under applicable laws.

Link:
Plandai Biotechnology, Inc. Announces the Closing of $13 Million Loan From the Land Bank of South Africa

OTTAWA, Ontario--(BUSINESS WIRE)--

David Allan, founding Chairman of YM BioSciences and its 13-year CEO is being recognized by the industry in BIOTECanadas naming him as recipient of the Gold Leaf Award for Industry Leadership. This award is given to an individual who demonstrates exemplary vision and leadership in Canadian biotechnology in a global context. He is being recognized for his commitment to promoting and supporting the growth of biotechnology in Canada.

David Allan has had an important impact on the recognition of Canadian biotechnology internationally with his unwavering commitment about the importance of international public and private capital markets as the lifeblood of the industry, commented Brad Thompson, Chair BIOTECanada. YM BioSciences has demonstrated versatility and resilience, utilizing international partnerships to offset the capital constraints faced by Canadian biotechnology companies. This is a model for many industry colleagues.

During his 17-year involvement with YM the company has enjoyed numerous "firsts" including being the first North American biotechnology company to float its IPO on the London Exchange, which occurred in 2002 simultaneously with listing on the TSX, as well, it is believed, as being the first company outside the United States to receive a Special Protocol Assessment from the FDA. Prior to YM David created the first science and technology-specific investment banking team in Canada to support the capital requirements of the biotechnology industry in the country and creating such novel biotechnology structures as Drug Royalty Corporation as well as YM BioSciences.

"I am thrilled that this 20-year commitment to the industry is being recognised by this exceptional and prestigious award. My commitment to the industry preceded my involvement with YM by being the first in Canada to import, in 1992, the model so successfully established in the United States of biotech-specific investment banks. From that experience came the recognition of the senseless chasm between the billions of dollars spent by our government-level programs supporting basic research and the low enthusiasm of Canadian venture capital funds and public capital markets in Canada to support the conversion of our scientific excellence into medicines useful for human health. I shall continue to work tirelessly, striving to eliminate the established impediments on accessing capital in Canada similarly to a prior successful engagement as Chair the Toronto Stock Exchange's Market Access Committee that created a specific framework encouraging previously unavailable financing of Small and Medium Enterprises through that exchange. I expect that my extensive experience in the management, M&A and financing of biotechnology companies will be useful as a mentor to others and I am delighted to continue broad involvement with the biotechnology industry in Canada as the Chair of YM, Executive Chair of Stem Cell Therapeutics Corp, Lead Director at DiaMedica Inc, and as Chairman of AvidBiologics Inc. in Toronto.

Join us as we celebrate industry leadership during the BIO International Convention at the Boston Convention & Exhibition Center. The Gold Leaf Awards ceremony will take place at the Canada Caf (booth number 735) June 19, 2012 in Boston, MA at 4pm.

Read the original here:
David Allan Lauded for Leadership – Biotechnology Leader Named to Industry Award

This is the main question that is lurking the minds of biologists for quite some time now because many possibilities for the occurrence of a homosexuality gene exist. During the 1990s many researcher were studying the topic but by the end of the 20th century all such research work was slowed down as many people are shy when they are asked on topics related to sex and specially homosexuality. Scientists Sergey Gavrilets and William Rice have developed some guidelines for explaining the causes of homosexuality. During the past decade the scientists have discovered some patterns that might point to genetic causes of homosexuality. Among the discoveries the main finding was that in case of male homosexuality it seems to be inherited more from the mother than the father and the female maternal relatives of gay men have higher that average reproduction capacity. Another shocking discovery was that the chances of homosexuality increases in males with the number of older brothers he has even if the child has grown up away from his brothers. The reason for this is that the with each male fetus the mother develops an increased immunization to an antigen that is produced by male fetuses and this antigen plays an important role in masculinizing the brain. All the studies have strong evidences that homosexuality is caused by a gene but no research has pointed to any specific gene and the idea to which each research points is towards a polymorphic gene. Rice commented that, ‘We know that homosexuality (gay or lesbian) can be caused by simple genetic changes in fruit flies, and since so many reproductive and neurological genes are shared by flies and humans, it seems highly likely that there are major genes influencing homosexuality in humans, However, we also have firm evidence for a birth-order effect on male homosexuality, and discordance in the expression of homosexuality of identical twins, so clearly there is also an environmental influence on the trait.’ This research is the most guiding research on the topic, though it also has not pointed out any particular gene but this will be the backbone of all future researchers that can one day tell us the exact cause of Homosexuality.

Source:
http://www.biotechblog.org/rss.xml

For more than 20 years, the main choice for breast implants has been some form of silicone rubber. Recent cancer research suggests nanotechnology may make breast implants safer as an alternative to silicone. Approximately 75 percent of post-mastectomy patients choose some form of breast reconstruction. While no medical device is free of risks, silicone breast implants still present a relatively high level of risk. This makes nanotechnology a promising alternative.

Similarly, nanotechnology may speed up recovery after breast reduction. Recovery from plastic surgery of any type has its risks. A University of Akron study suggests that nanotechnology produces additional properties that offer additional medical benefits patients cannot get from silicone or other traditional procedures. Some of the potential dangers of silicone materials include a greater instance of various forms of cancer, systemic diseases and psychological diseases. Dr. Judit E. Puskas, who led the study at the University of Akron, believes that nanostructured material may eliminate such risks and present a safer alternative to silicone-based breast implants.

Dr. Laura Kruper of the City of Hope Medical Center in Duarte, California is among doctors pointing out the psychological benefits of reconstruction following a mastectomy. While expense is a concern for some women, another factor is safety. This adds to the appeal of materials constructed using nanotechnology. The idea of using nanotechnology in breast implants is to alter the characteristics of the silicone. The manipulation would take place in the atoms of the silicone. Implants with the capability of delivering chemicals may speed up the recovery process and reduce side effects following surgery and initial treatment.

According to the Centers for Disease Control and Prevention, breast cancer is the most common cancer among women in the United States. It is the leading cause of death among women of all races. While breast cancer rates have been decreasing by about 2 percent since 2005, it is still estimated that 1 in 8 women will develop some form of breast cancer during their lifetime. This makes exploration of nanotechnology a worthwhile effort, according to Dr. Puskas and other doing similar research. The primary goal is to ensure that such technology is safe. Early research has shown promise. Some researchers have gone beyond Dr. Puskas’ early optimism and suggest that nanotechnology may result in materials that are not only safer, but materials that have the ability to deliver cancer medications more directly.

Nanostructured materials, by nature, are smaller. This includes smaller components within the material that minimizes complications. The new material will also have the ability to deliver certain cancer drugs more locally. The ability to deliver cancer drugs in this manner could help patients who have a breast reduction or have to have a mastectomy or double mastectomy due to breast cancer. Delivering cancer drugs this way could further minimize risks and side effects associated with chemotherapy. Right now, such technology is in the testing phase. The goal of nanotechnology research is to create alternatives to silicone implants that sharply reduce side effects and potential risks at the time of the implants and in the future. According to Breastcancer.org, there are about 3 million breast cancer survivors in the United States. A common concern among survivors, especially those who had some form of mastectomy or lumpectomy, is finding a way to restore the natural appearance of the breast.

Some women express a hesitation to get breast implants following breast cancer due to a fear that the implants themselves will cause additional medical problems. According to a study of breast cancer patients in California, fewer women are electing to have breast implants following mastectomy. On a nationwide level, however, statistics show that about 90 percent of women who have had a mastectomy following breast cancer choose some form of reconstruction. Nanotechnology is showing promise among all fields of science, but still must receive FDA approval to be used in breast implants. Early studies, however, are highlighting the potential of nanotechnology.

Source:
http://www.biotechblog.org/rss.xml

Background:
Pretreatment is an essential step in the enzymatic hydrolysis of biomass for bio-ethanol production. The dominant concern in this step is how to decrease the high cost of pretreatment while achieving a high sugar yield. Fungal pretreatment of biomass was previously reported to be effective, with the advantage of having a low energy requirement and requiring no application of additional chemicals. In this work, Gloeophyllum trabeum KU-41 was chosen for corn stover pretreatment through screening with 40 strains of wood-rot fungi. The objective of the current work is to find out which characteristics of corn stover pretreated with G. trabeum KU-41 determine the pretreatment method to be successful and worthwhile to apply. This will be done by determining the lignin content, structural carbohydrate, cellulose crystallinity, initial adsorption capacity of cellulase and specific surface area of pretreated corn stover.
Results:
The content of xylan in pretreated corn stover was decreased by 43% in comparison to the untreated corn stover. The initial cellulase adsorption capacity and the specific surface area of corn stover pretreated with G. trabeum were increased by 7.0- and 2.5-fold, respectively. Also there was little increase in the cellulose crystallinity of pretreated corn stover.
Conclusion:
G. trabeum has an efficient degradation system, and the results indicated that the conversion of cellulose to glucose increases as the accessibility of cellulose increases due to the partial removal of xylan and the structure breakage of the cell wall. This pretreatment method can be further explored as an alternative to the thermochemical pretreatment method.Source:
http://www.biotechnologyforbiofuels.com/rss/

Background:
The recent discovery of accessory proteins that boost cellulose hydrolysis has increased the economical and technical efficiency of processing cellulose to bioethanol. Oxidative enzymes (e.g. GH61) present in new commercial enzyme preparations have shown to increase cellulose conversion yields. When using pure cellulose substrates it has been determined that both oxidized and unoxidized cellodextrin products are formed. We report the effect of oxidative activity in a commercial enzyme mix (Cellic CTec2) upon overall hydrolysis, formation of oxidized products and impact on beta-glucosidase activity. The experiments were done at high solids loadings using a lignocellulosic substrate simulating commercially relevant conditions.
Results:
The Cellic CTec2 contained oxidative enzymes which produce gluconic acid from lignocellulose. Both gluconic and cellobionic acid were produced during hydrolysis of pretreated wheat straw at 30% WIS. Up to 4% of released glucose was oxidized into gluconic acid using Cellic CTec2, whereas no oxidized products were detected when using an earlier cellulase preparation Celluclast/Novozym188. However, the cellulose conversion yield was 25% lower using Celluclast/Novozym188 compared to Cellic CTec2. Despite the advantage of the oxidative enzymes, it was shown that aldonic acids could be problematic to the hydrolytic enzymes. Hydrolysis experiments revealed that cellobionic acid was hydrolyzed by beta-glucosidase at a rate almost 10-fold lower than for cellobiose, and the formed gluconic acid was an inhibitor of the beta-glucosidase.Interestingly, the level of gluconic acid varied significantly with temperature. At 50C (SHF conditions) 35% less gluconic acid was produced compared to at 33C (SSF conditions). We also found that in the presence of lignin, no reducing agent is needed for the function of the oxidative enzymes.
Conclusions:
The presence of oxidative enzymes in Cellic CTec2 led to the formation of cellobionic and gluconic acid during hydrolysis of pretreated wheat straw and filter paper. Gluconic acid was a stronger inhibitor of beta-glucosidase than glucose. The formation of oxidized products decreased as the hydrolysis temperature was increased from 33C to 50C. Despite end-product inhibition, the oxidative cleavage of the cellulose chains has a synergistic effect upon the overall hydrolysis of cellulose as the sugar yield increased compared to using an enzyme preparation without oxidative activity.Source:
http://www.biotechnologyforbiofuels.com/rss/

Background:
A major challenge in the identification and development of superior feedstocks for the production of second generation biofuels is the rapid assessment of biomass composition in a large number of samples. Currently, highly accurate and precise robotic analysis systems are available for the evaluation of biomass composition, on a large number of samples, with a variety of pretreatments. However, the lack of an inexpensive and high-throughput process for large scale sampling of biomass resources is still an important limiting factor. Our goal was to develop a simple mechanical maize stalk core sampling device that can be utilized to collect uniform samples of a dimension compatible with robotic processing and analysis, while allowing the collection of hundreds to thousands of samples per day.
Results:
We have developed a core sampling device (CSD) to collect maize stalk samples compatible with robotic processing and analysis. The CSD facilitates the collection of thousands of uniform tissue cores consistent with high-throughput analysis required for breeding, genetics, and production studies. With a single CSD operated by one person with minimal training, more than 1,000 biomass samples were obtained in an eight-hour period. One of the main advantages of using cores is the high level of homogeneity of the samples obtained and the minimal opportunity for sample contamination. In addition, the samples obtained with the CSD can be placed directly into a bath of ice, dry ice, or liquid nitrogen maintaining the composition of the biomass sample for relatively long periods of time.
Conclusions:
The CSD has been demonstrated to successfully produce homogeneous stalk core samples in a repeatable manner with a throughput substantially superior to the currently available sampling methods. Given the variety of maize developmental stages and the diversity of stalk diameter evaluated, it is expected that the CSD will have utility for other bioenergy crops as well.Source:
http://www.biotechnologyforbiofuels.com/rss/

GUANGZHOU, China, May 3, 2012 /PRNewswire-Asia/ -- Johnson & Johnson (China) Investment Ltd. today announced it has acquired Guangzhou Bioseal Biotechnology Co., Ltd. (Bioseal) a privately held biopharmaceutical company specializing in the design, development and commercialization of a porcine plasma-derived biologic product for controlling bleeding during surgery. The acquisition was completed after obtaining all necessary Chinese Government approvals. Financial terms of the transaction are not being disclosed.

"This transaction reinforces our commitment to China and delivering innovative medical device solutions to the Chinese market," said Xie Wen Jian President of Johnson & Johnson Medical China. "We are very pleased to add the BIOSEAL brand to our growing portfolio of hemostasis products in China and we look forward to working with our new Bioseal colleagues to bring their innovative products to more physicians and patients."

Bioseal manufactures a porcine-derived fibrin sealant, BIOSEAL, currently the only porcine plasma-derived fibrin sealant approved for use in China. Fibrin sealants are used by surgeons as an adjunct to hemostasis for use in patients undergoing surgery, when control of bleeding by standard surgical techniques is ineffective or impractical.

Bioseal will work closely with Ethicon, Inc., a Johnson & Johnson Company, which offers the world's most complete line of absorbable hemostats with a commitment to advancing the future of biosurgery beyond hemostasis, to seal leaks, join structures and enhance healing. Ethicon biosurgery brands already on the market in China include SURGICEL and SURGIFLO.

"By adding Bioseal to the existing line of Ethicon hemostasis products sold in China, we aspire to shape the broader biosurgery market in Asia by providing physicians and their patients with an even greater variety of innovative and clinical-based solutions to address bleeding, sealing and leaking challenges," said Michael del Prado, Company Group Chairman, Johnson & Johnson Medical Asia Pacific.

This is the first acquisition in the medical device industry for Johnson & Johnson (China). The corporation has been doing business in China for more than 25 years, including establishing a new innovation center in China last year to design and develop medical devices and diagnostic products specifically for Asia's emerging markets. This acquisition reinforces our long-standing commitment to providing medical solutions in Asia that help to improve the standard of health care for millions of people in the region.

The acquisition of Bioseal will complement Ethicon's existing biosurgery portfolio and will allow the business to immediately enter the fibrin sealant market in China, broaden product offerings and create an opportunity to increase global reach by introducing advanced biologic solutions that meet the various needs of more physicians and patients, throughout Asia and around the world.

About Johnson & Johnson (China) Investment Ltd.

Johnson & Johnson (China) Investment Ltd. is a foreign investment entity established in China by Johnson & Johnson in 1998. For more information about Johnson & Johnson and its operating units in China, please visit http://www.jnj.com.cn.

About Ethicon, Inc.

Read more:
Johnson & Johnson (China) Investment Ltd. Acquires Guangzhou Bioseal Biotechnology Co., Ltd.

WASHINGTON--(BUSINESS WIRE)--

Mark J. Riedy, a Member of the Corporate & Securities Section and Energy & Clean Technology Practice at Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C., will give a plenary address at the World Congress on Biotechnology & Bioprocessing hosted by the Biotechnology Industrial Organization (BIO). The congress is being held April 29-May 2 in Orlando, Florida.

Mr. Riedy will be a featured speaker at the plenary session entitled, Financing Innovation in the Industrial Biotech Space: Creative Models and Future Trends. The panel will take place on Wednesday, May 2nd from 8:00 am to 10:00 am.

The BIO World Congress on Industrial Biotechnology and Bioprocessing is the world's largest industrial biotechnology event for business leaders, investors and policy makers. The 9th annual conference will bring together more than 1,000 attendees and feature presentations on the latest industry developments. The event will include more than 35 sessions led by biofuel and renewable chemical company executives, scientists and government officials.

In his more than 35 years of practice, Mr. Riedy has represented clients in domestic and international corporate finance matters, including energy and infrastructure, project development and debt and equity financing, mergers and acquisitions, technology outsourcing, investment fund structuring, venture capital structuring, and regulatory and legislative issues. He also has represented clients in international disputes before U.S. and foreign agencies, dealing with matters such as anti-dumping, export controls, sanctions, and anti-bribery. Mr. Riedy has counseled renewable and conventional energy and infrastructure clients doing business in more than 50 countries.

Mr. Riedy is one of the founders and general counsel of the American Council On Renewable Energy (ACORE), the largest domestic and international association of renewable energy and clean tech businesses. Over the years, he has lead the DC Technology Funders, a monthly breakfast meeting which brings together up to 40 venture capital and private equity funders for presentations by new clean tech companies seeking funding. Additionally, Mr. Riedy has served as general counsel and a longtime board member (currently board member emeritus) for the US-India Business Council, the largest U.S.-India business association, general counsel of the Clean Fuels Development Coalition and he is Vice Chairman of the American Bar Association's Project Finance Committee. He has the honor of an AV rating by Martindale-Hubbell and was recently named one of the Top 100 Bioenergy Leaders in the world by Biofuels Digest.

Mr. Riedy received his B.A., summa cum laude, from the University of Michigan and his J.D. from the Georgetown University Law Center.

For more information about BIOs World Congress on Biotechnology & Bioprocessing, please click here.

For more information about Mintz Levin, please click here.

Read more:
Mintz Levin Attorney Mark J. Riedy to Speak at World Congress on Biotechnology & Bioprocessing

EAST SETAUKET,N.Y., May 1, 2012 /PRNewswire/ --John S. Kovach, M.D., Chair, Board of Directors and CEO of Lixte Biotechnology Holdings, Inc. (LIXT.PK), announced the submission of an IND application to the Food and Drug Administration to conduct a Phase I trial of its lead, anti-cancer compound, LB-100.

Dr. Kovach said, "We believe that LB-100, a novel anti-cancer compound, prevents cancer cells from defending themselves against standard types of cancer treatments. In pre-clinical animal models of cancer, LB-100 inhibits cancer cell growth on its own but, more importantly, it significantly enhances the killing of cancer cells by several widely used anti-cancer drugs including Temozlomide, Doxorubicin, and Docetaxel as well as radiation. In the initial Phase I trial to be conducted at a nationally recognized comprehensive cancer center, LB-100 will be evaluated alone and in combination with a standard anti-cancer drug. We hope that the improved anti-cancer activity of LB-100 combined with conventional anti-cancer treatments in animal models is borne out in the clinic without undue toxicity. If so, we believe that regimens containing LB-100 will be associated with meaningful benefit to patients with a number of different types of cancer."

About Lixte Biotechnology Holdings, Inc. Lixte is engaged in development of improved treatments for cancer. The company was created to capitalize on opportunities to develop low cost, specific and sensitive tests for the early detection of cancers. Over the past four years, however, Lixte has evolved into what is now primarily a cancer drug discovery company, using biomarker technology to identify vulnerable anti-cancer targets and then create novel compounds to attack those targets.

The Company is developing new treatments for several cancers for which better treatments are urgently needed. The initial focus was on the most aggressive type of brain cancer of adults and children but now includes other cancers including breast, pancreas, stomach, and melanomas and sarcomas.

Forward-Looking StatementsThis announcement contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, and Section 21E of the Securities Exchange Act of 1934. For example, statements regarding the Company's financial position, business strategy and other plans and objectives for future operations, and assumptions and predictions about future product demand, supply, manufacturing, costs, marketing and pricing factors are all forward-looking statements. These statements are generally accompanied by words such as "intend," anticipate," "believe," "estimate," "potential(ly)," "continue," "forecast," "predict," "plan," "may," "will," "could," "would," "should," "expect" or the negative of such terms or other comparable terminology. The Company believes that the assumptions and expectations reflected in such forward-looking statements are reasonable, based on information available to it on the date hereof, but the Company cannot provide assurances that these assumptions and expectations will prove to have been correct or that the Company will take any action that the Company may presently be planning. However, these forward-looking statements are inherently subject to known and unknown risks and uncertainties. Actual results or experience may differ materially from those expected or anticipated in the forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, regulatory policies, available cash, research results, competition from other similar businesses, and market and general economic factors. This discussion should be read in conjunction with the condensed consolidated financial statements and notes thereto in the Quarterly Report on Form 10K for the year ending December 31, 2011.

For additional information, please see: http://www.Lixte.com

More:
Lixte Biotechnology Holdings Announces Submission of an IND to the FDA for Approval of a Clinical Trial of LB-100, a ...

WASHINGTON--(BUSINESS WIRE)--

The Biotechnology Industry Organization (BIO) announced today its selection of Representative Mike Rogers (R-MI) as Legislator of the Year for 2011-2012. Representative Rogers receives the award in conjunction with todays BIO Legislative Day Fly-In reception.

"Representative Rogers' achievements on the Energy and Commerce Committee have been instrumental for the growth of the life science industry, which is researching and developing new cures and treatments for debilitating diseases, and providing cutting-edge technologies to improve crop yields, and discover cleaner forms of home-grown energy," said BIO President and CEO Jim Greenwood. We salute him for introducing and supporting critically important legislation, including the Pandemic and All Hazard Preparedness Act, the Best Pharmaceuticals for Children Act and the Pediatric Research Equity Act.

Representative Rogers has quickly established himself as a champion of the biotechnology industry, both here in Michigan and throughout America. We appreciate his consistent support for this industry that provides almost 40,000 high-paying jobs in this state alone," said Stephen Rapundalo, PhD, MichBio President & CEO.

More than 200 biotechnology industry representatives from 41 states will participate in hundreds of meetings with Members of the House and Senate during the BIO Legislative Day Fly-In.Participants will discuss issues critical to the biotechnology industry including reauthorization of the Prescription Drug User Fee Act, the Transforming the Regulatory Environment to Accelerate Access to Treatments (TREAT) Act/Faster Access to Specialized Treatments (FAST) Act, adequate reimbursement for vital therapies under Medicare, and capital formation issues relevant to biotechnology companies.

Photos of the award presentation are available upon request.

BIO represents more than 1,100 biotechnology companies, academic institutions, state biotechnology centers and related organizations across the United States and in more than 30 other nations. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology products. BIO also produces the BIO International Convention, the worlds largest gathering of the biotechnology industry, along with industry-leading investor and partnering meetings held around the world.

See more here:
Representative Rogers Honored as BIO Legislator of the Year

Some business-minded folks in Charlottesville say there's a biotechnology boom happening in the city, one that could certainly bolster the bottom line for the economy in the area.

Those familiar with the industry's growth say Charlottesville may not be in the ranks of California's Silicon Valley or North Carolina's Research Triangle quite yet, but 35 thriving biotech companies have started up in the city so far, and they only anticipate more to come. The research and ideas coming from the University Of Virginia are being credited with being a huge push for biotechnology business starting up in Charlottesville.

Armed with test tubes and lab coats, scientists at INDOOR Biotechnologies spend their days testing out allergens in their small space on Harris Street, but they're gearing up for a big move. From bottling to biotechnology, CEO Martin Chapmanwill soon move his company into the old Coca Cola plant on Preston Avenue. He hopes to use that space to not only expand his own business, but also to help other science-based companies start up in the city.

"We've developed our plan around that, to develop it as a space for us and also an incubator new biotech companies," Chapman explained.

After taking his UVA research to his company, Chapman says what made him settle on Charlottesville is far from scientific. Rather, it's as simple as the resources and smarts the town has to offer him.

"Charlottesville attracts talented people," Chapman added.

Chapman says the success of INDOOR Biotechnologies is just one example of this industry's growth in the area. In fact, according to his count, about 35 biotech companies are providing more than 100 jobs to people in the city.

"Its happening and there's a lot of impetus in the industry at the moment to push things forward," Chapman said.

Helping to fuel the progress, UVA Innovation Partnerships Executive Director Mark Crowell says world-class research is great to have, but even better when companies are capitalizing on it.

"There's a lot of things we can do to sort of nurture the companies and nurture the community, attract the talent, retain the talent, and help the companies through that initial growth spurt," Crowell said.

Link:
Biotechnology Booming In Charlottesville

24-04-2012 05:39 Highlights of an industrial visit by a delegation of Thai technology-based entrepreneurs and scientists to booming biotechnology and IT industries in and around Bangalore. The one-week study visit took place in March 2012. It was partially supported by Thailand's Department of International Economic Affairs, Ministry of Foreign Affairs in cooperation with National Science and Technology Development Agency (NSTDA). The delegates visited Biocon, Infosys, Sartorius Stedim India, Metahelix Life Sciences, Bhat Bio-Tech India, Association of Biotechnology Led Enterprises (ABLE), Institute of Bioinformatics and Applied Biotechnology (IBAB), Visvesvaraya Industrial and Technological Museum, and Government of Karnataka's Department of Information Technology and Biotechnology. Sightseeing sites visited include Lal Bagh Botanical Garden, Brigade Road, MG Road, ISKCON Temple, Tipu Palace, Bangalore Palace, and Nandi Hills.

More:
Bangalore Biotechnology

WASHINGTON--(BUSINESS WIRE)--

The Biotechnology Industry Organization (BIO) announced today its selection of Senator Kay Hagan (D-NC) as Legislator of the Year for 2011-2012. Senator Hagan receives the award in conjunction with todays BIO Legislative Day Fly-In reception.

As the sponsor of the TREAT Act, Senator Hagan has offered renewed hope to patients desperately in need of cures and breakthrough new medicines as well as a boost to our nations economy. The legislation will help the U.S. Food and Drug Administration (FDA) retain its leadership position as the global gold standard for regulatory science and consumer protection, said BIO President and CEO Jim Greenwood.

Senator Hagan has distinguished herself as a strong leader for national policy that will help our nations biotechnology sector thrive and benefit people everywhere.She is a proven advocate for patient care and preserving incentives for innovation, said Sam Taylor, President of the North Carolina Biosciences Organization. On behalf of all North Carolina life sciences companies, we salute Senator Hagan's efforts.She is a true friend to our bioscience community and the patients that we serve."

More than 200 biotechnology industry representatives from 41 states will participate in hundreds of meetings with Members of the House and Senate during the BIO Legislative Day Fly-In.Participants will discuss issues critical to the biotechnology industry including reauthorization of the Prescription Drug User Fee Act, the Transforming the Regulatory Environment to Accelerate Access to Treatments (TREAT) Act/Faster Access to Specialized Treatments (FAST) Act, adequate reimbursement for vital therapies under Medicare, and capital formation issues relevant to biotechnology companies.

Photos of the award presentation are available upon request.

BIO represents more than 1,100 biotechnology companies, academic institutions, state biotechnology centers and related organizations across the United States and in more than 30 other nations. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology products. BIO also produces the BIO International Convention, the worlds largest gathering of the biotechnology industry, along with industry-leading investor and partnering meetings held around the world.

See the original post here:
Senator Hagan Honored as BIO Legislator of the Year

WASHINGTON--(BUSINESS WIRE)--

The Biotechnology Industry Organization (BIO) announced today its selection of Senator Michael Enzi (R-WY) as a Legislator of the Year for 2011-2012. Senator Enzi receives the award in conjunction with todays BIO Legislative Day Fly-In reception.

"As the ranking minority member of the Committee on Health, Education, Labor, and Pensions, Senator Enzi has been instrumental to the growth of the life science industry. Thanks to his support, American doctors and scientists are better able to translate innovative research into new cures and treatments for debilitating diseases, such as multiple sclerosis and HIV/AIDS, and provide cutting-edge technologies to improve crop yields, and discover cleaner forms of home-grown energy," said BIO President and CEO Jim Greenwood.As a champion of American biotechnology, his steadfast support for a timely reauthorization of the Prescription Drug User Fee Act, as well as efforts to ensure reforms to the Accelerated Approval pathway at the FDA, reflect a keen understanding of important healthcare issues.

More than 200 biotechnology industry representatives from 41 states will participate in hundreds of meetings with Members of the House and Senate during the BIO Legislative Day Fly-In.Participants will discuss issues critical to the biotechnology industry including reauthorization of the Prescription Drug User Fee Act, the Transforming the Regulatory Environment to Accelerate Access to Treatments (TREAT) Act/Faster Access to Specialized Treatments (FAST) Act, adequate reimbursement for vital therapies under Medicare, and capital formation issues relevant to biotechnology companies.

Photos of the award presentation are available upon request.

BIO represents more than 1,100 biotechnology companies, academic institutions, state biotechnology centers and related organizations across the United States and in more than 30 other nations. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology products. BIO also produces the BIO International Convention, the worlds largest gathering of the biotechnology industry, along with industry-leading investor and partnering meetings held around the world.

Visit link:
Senator Enzi Honored as BIO Legislator of the Year